eNewsroom for: Alliqua

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/alliqua/Screen-Shot-2013-08-02-at-11.08.22-AM.png

Alliqua Company Profile

Alliqua, Inc. (OTCBB: ALQA) is a wound management and drug delivery company that creates superior outcomes for patients, providers, and partners through its platform technology and proprietary products. Our core businesses include advanced wound care, transdermal drug delivery, and contract manufacturing. We leverage our proprietary hydrogel technology platform to add value to our own products and also those of our partners. Wound Management In the area of advanced wound care, we manufacture and market a line of proprietary advanced wound dressings that include: SilverSeal®: A flexible, sterile, non-adherent hydrogel dressing that incorporates the antimicrobial properties of metallic silver coated fiber. Hydress®: A flexible, sterile, non-adherent hydrogel dressing that can absorb two-times its weight in exudate. We are in the process of expanding our advanced wound care portfolio to better meet the needs of clinicians and the patients they serve. This suite of differentiated advanced wound care products will enhance their ability to effectively and efficiently manage a variety of wound indications and wound conditions throughout the healthcare continuum. Transdermal Drug Delivery In the area of transdermal drug delivery, our hydrogel technology can be used to deliver therapeutic compounds through the skin. Key advantages of our delivery platform include stability of form and composition, purity, reproducibility, and compatibility with various active ingredients. Within certain patient populations, transdermal drug delivery has multiple advantages over oral drug delivery or injections. Alliqua hydrogels provide a welcome texture and flexibility for the patients; their ease of administration is an added bonus. We intend to commercialize our drug delivery platform in multiple therapeutic areas. Contract Manufacturing Our contract manufacturing business unit provides custom hydrogels to the OEM market. We develop and manufacture electron-beam cross-linked sheet gels for customers that include manufacturers of medical devices, cosmeceuticals, and other commercial product applications. Our ability to meet the varying specifications of our customers, while maintaining tight tolerances and ensuring delivery on-time and within budget, has made us a leader in the electron beam cross-linked hydrogel market.

News from Alliqua:

Not Found

Sorry, but there aren't any posts by Alliqua yet.